Aaron Kesselheim
@akesselheim
Professor of Medicine, Harvard Medical School; Director, Program On Regulation, Therapeutics, And Law (PORTAL), Brigham and Women's Hospital
ID: 22104276
http://www.portalresearch.org 27-02-2009 03:55:10
838 Tweet
5,5K Takipçi
273 Takip Edilen
Yesterday, filed an amicus brief in the Amgen v Sanofi SCOTUS Updates case detailing why undeserved broad drug patents harm patients and innovation, w/ Jerry Avorn, National Center for Health Research, Arnold Ventures, & others. Thanks to the great team at Fish & Richardson: supremecourt.gov/DocketPDF/21/2…
Interesting point by Sean Dickson… maybe the new Medicaid rebate rules were one of the factors driving Lilly to lower list prices. Aaron Kesselheim and I wrote about this in JAMA Internal Medicine back in 2021: jamanetwork.com/journals/jamai…
Great article from Zach Brennan Endpoints News today covering our new work Health Affairs on inhaler patents and litigation. Where are all the generic inhalers for asthma and COPD? Researchers call for patent and FDA reforms - endpts.com/where-are-all-…
Policy makers have several options to maximize benefits from public investments and improve returns for the entire global community, write Hussain Lalani, MD, MPH, MSc, Sarosh Nagar, Jerry Avorn, and Aaron Kesselheim. trib.al/TmiXjUb
Watch Program On Regulation, Therapeutics, And Law Ameet Sarpatwari speak at today's SenateHELP Committee hearing on COVID vaccine pricing -- and check out our The Boston Globe op-ed from Hussain Lalani, MD, MPH, MSc on the public funding critical to its development: bostonglobe.com/2023/03/21/opi…
Is It Business as Usual for the Drug Industry? In MedPage Today, Alex Egilman, Aaron Kesselheim, and I explain why drug companies continued to raise prices in 2023 despite the #InflationReductionAct medpagetoday.com/opinion/second…
Prior authorization requirements for 1/3 of new drugs in Medicare Part D are more restrictive than FDA labeling, according this cross-sectional study. LSE Health Policy Research Portal Aaron Kesselheim Robin Forrest ja.ma/3lK4vCD
Thanks for a great presentation karim / sariahmed.bsky.social!
Despite new penalties via the #InflationReductionAct, drug companies raised prices for nearly 1k drugs in January. Is Congress' attempt to curb drug price hikes failing? Read the #OpEd by Alexander C. Egilman, Aaron Kesselheim & Ben Rome of Program On Regulation, Therapeutics, And Law. bit.ly/3lVo9vA
Important session next week on racial discrimination and pulse oximetry in the Program On Regulation, Therapeutics, And Law and Center for Bioethics health policy and bioethics consortium! Register please!
New cross-sectional study finds that more than half of #AcceleratedApproval confirmatory trials are completed after the deadline set by the FDA. Aaron Kesselheim Ben Rome Program On Regulation, Therapeutics, And Law ja.ma/3KndEuB
Introduction of a citrate-free version of adalimumab in 2018 avoided Medicaid's inflationary rebates and led to >$4B excess spending from 2018-2021. ja.ma/3SP2qlf Charlie ChangWon Lee Aaron Kesselheim Ben Rome Program On Regulation, Therapeutics, And Law